• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌射频消融术后实验室检查结果的改变:与潜在肝脏疾病严重程度及消融体积的关系

Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume.

作者信息

Shin Sang-Wook, Jeong Woo Kyoung, Lim Sanghyeok, Kim Yongsoo, Kim Jinoo

机构信息

Department of Radiology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.

Department of Radiology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea. ; Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2015 Mar;21(1):71-9. doi: 10.3350/cmh.2015.21.1.71. Epub 2015 Mar 25.

DOI:10.3350/cmh.2015.21.1.71
PMID:25834804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4379200/
Abstract

BACKGROUND/AIMS: To investigate sequential changes in laboratory markers after radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) and the relationship of these changes to the severity of the underlying liver disease.

METHODS

This retrospective analysis included 65 patients (44 males, 21 females) who underwent RFA of HCC. Hematologic and biochemical markers were assessed at the pre-RFA period and 1 day, 2-3 days, and 1-2 weeks after RFA. We classified the subjects into two groups: Child-Pugh A (n=41) and Child-Pugh B (n=24). The ablative margin volume (AMV) of each patient was measured. We analyzed the changes in laboratory profiles from the baseline, and investigated whether these laboratory changes were correlated with the AMV and the Child-Pugh classification.

RESULTS

Most of the laboratory values peaked at 2-3 days after RFA. AMV was significantly correlated with changes in WBC count, hemoglobin level, and serum total bilirubin level (Pearson's correlation coefficient, 0.324-0.453; P<0.05). The alanine aminotransferase (ALT) level varied significantly over time (P=0.023).

CONCLUSIONS

Most of the measured laboratory markers changed from baseline, peaking at 2-3 days. The ALT level was the only parameter for which there was a significant difference after RFA between Child-Pugh A and B patients: it increased significantly more in the Child-Pugh A patients.

摘要

背景/目的:研究肝细胞癌(HCC)射频消融(RFA)后实验室指标的连续变化及其与潜在肝脏疾病严重程度的关系。

方法

这项回顾性分析纳入了65例行HCC射频消融术的患者(44例男性,21例女性)。在RFA术前、术后1天、2 - 3天以及1 - 2周评估血液学和生化指标。我们将受试者分为两组:Child-Pugh A级(n = 41)和Child-Pugh B级(n = 24)。测量每位患者的消融边缘体积(AMV)。我们分析了实验室指标相对于基线的变化,并研究这些实验室变化是否与AMV及Child-Pugh分级相关。

结果

大多数实验室值在RFA后2 - 3天达到峰值。AMV与白细胞计数、血红蛋白水平及血清总胆红素水平的变化显著相关(Pearson相关系数,0.324 - 0.453;P < 0.05)。丙氨酸氨基转移酶(ALT)水平随时间有显著变化(P = 0.023)。

结论

大多数测量的实验室指标与基线相比发生了变化,在2 - 3天达到峰值。ALT水平是Child-Pugh A级和B级患者RFA后唯一有显著差异的参数:Child-Pugh A级患者的ALT水平升高更为显著。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7342/4379200/e49e13a90a3c/cmh-21-71-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7342/4379200/611ac5ec79cf/cmh-21-71-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7342/4379200/0ffffc54ac08/cmh-21-71-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7342/4379200/e49e13a90a3c/cmh-21-71-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7342/4379200/611ac5ec79cf/cmh-21-71-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7342/4379200/0ffffc54ac08/cmh-21-71-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7342/4379200/e49e13a90a3c/cmh-21-71-g003.jpg

相似文献

1
Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume.肝细胞癌射频消融术后实验室检查结果的改变:与潜在肝脏疾病严重程度及消融体积的关系
Clin Mol Hepatol. 2015 Mar;21(1):71-9. doi: 10.3350/cmh.2015.21.1.71. Epub 2015 Mar 25.
2
Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis.射频消融治疗失代偿期肝硬化肝癌。
Oncology. 2011;81(1):39-44. doi: 10.1159/000331411. Epub 2011 Sep 9.
3
The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma.经导管动脉化疗栓塞联合经皮射频消融治疗肝细胞癌对肝功能的影响。
J Formos Med Assoc. 2012 Sep;111(9):510-5. doi: 10.1016/j.jfma.2011.05.016. Epub 2012 Jul 24.
4
[Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma].[射频消融治疗晚期肝细胞癌的疗效]
Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):256-60. doi: 10.3760/cma.j.issn.1007-3418.2012.04.006.
5
Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment.接受射频消融作为一线治疗的肝细胞癌患者的十年生存率。
World J Gastroenterol. 2016 Mar 14;22(10):2993-3005. doi: 10.3748/wjg.v22.i10.2993.
6
Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study.肝细胞癌腹腔镜射频热消融术后生存的预测因素:一项前瞻性研究。
Surg Endosc. 2005 May;19(5):710-4. doi: 10.1007/s00464-004-8815-z. Epub 2005 Mar 11.
7
The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.射频消融治疗肝细胞癌(>2cm 且<5cm)所需的最小消融边界以预防局部肿瘤进展:使用 CT 图像融合的 3D 定量评估。
AJR Am J Roentgenol. 2010 Sep;195(3):758-65. doi: 10.2214/AJR.09.2954.
8
Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.消融后去γ-羧基凝血酶原水平可预测乙型肝炎相关肝细胞癌的预后。
Liver Int. 2016 Apr;36(4):580-7. doi: 10.1111/liv.12991. Epub 2015 Nov 18.
9
[Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy].肝切除术后复发性肝细胞癌的射频消融术
Zhonghua Wai Ke Za Zhi. 2005 Aug 1;43(15):980-4.
10
Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes.困难部位肝细胞癌的射频消融:策略与长期疗效
World J Gastroenterol. 2015 Feb 7;21(5):1554-66. doi: 10.3748/wjg.v21.i5.1554.

引用本文的文献

1
Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study.乐伐替尼与射频消融联合治疗超出米兰标准且肝功能为Child-Pugh A级的中期肝细胞癌患者:一项前瞻性研究。
Front Oncol. 2022 May 4;12:843680. doi: 10.3389/fonc.2022.843680. eCollection 2022.

本文引用的文献

1
Biochemical diagnosis of liver disease.肝病的生化诊断
Indian J Clin Biochem. 1999 Jan;14(1):59-90. doi: 10.1007/BF02869152.
2
Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma.血小板减少症代表着肝癌患者射频消融后肝功能恶化的风险。
Clin Mol Hepatol. 2012 Sep;18(3):302-8. doi: 10.3350/cmh.2012.18.3.302. Epub 2012 Sep 25.
3
Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
经动脉肝化疗栓塞术治疗伴合成性肝功能障碍的肝细胞癌患者的发病率和死亡率。
Liver Transpl. 2013 Feb;19(2):164-73. doi: 10.1002/lt.23552. Epub 2012 Dec 12.
4
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南:肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
5
Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.肝癌伴腹水患者经肝动脉化疗栓塞术后肝功能衰竭:发生率、危险因素及预后预测。
J Clin Gastroenterol. 2011 Jul;45(6):556-62. doi: 10.1097/MCG.0b013e318210ff17.
6
Biochemical and hematologic changes after percutaneous radiofrequency ablation of liver tumors: experience in 83 procedures.经皮射频消融治疗肝脏肿瘤后的生化和血液学变化:83 例经验。
J Vasc Interv Radiol. 2011 Apr;22(4):471-8. doi: 10.1016/j.jvir.2010.12.033.
7
Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension.使用 Laennec 纤维化评分系统对肝硬化进行组织学分类与临床分期和门静脉高压程度相关。
J Hepatol. 2011 Nov;55(5):1004-9. doi: 10.1016/j.jhep.2011.02.012. Epub 2011 Feb 24.
8
Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma.经皮射频消融治疗肝细胞癌患者肝功能参数的变化。
Hepatol Res. 2010 May;40(5):550-4. doi: 10.1111/j.1872-034X.2009.00613.x.
9
Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion.经皮肿瘤消融治疗肝细胞癌后肝储备功能的变化:227 例单发肿瘤患者的长期随访。
Hepatol Int. 2007 Jun;1(2):295-301. doi: 10.1007/s12072-007-9001-x.
10
Radiofrequency ablation for unresectable tumors of the liver.射频消融治疗不可切除的肝脏肿瘤。
Am Surg. 2008 Jul;74(7):594-600; discussion 600-1.